Alimentary pharmacology & therapeutics · 2025
Serum Villin-1-A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tornai David, Balogh Boglarka, Csillag Aniko, Budai Andras, Kiss Andras, Antal-Szalmas Peter, Mehes Gabor, Barath Lukacs, Tornai Tamas, Tornai Istvan, Vitalis Zsuzsanna, Sipeki Nora, Dinya Tamas, Enyedi Attila, Rosenberger Florian A, Laleman Wim, Coenraad Minneke J, Aguilar Ferran, Claria Joan, Moreau Richard, Trebicka Jonel, Papp Maria, MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium
Аннотация
BACKGROUND: Gut barrier dysfunction contributes to acute decompensation (AD) of cirrhosis progression but, it is not acknowledged in severity or prognostic scores due to a lack of appropriate assessment tools.
AIM: We investigated serum villin-1 (VIL1), an epithelial brush-border associated actin-binding protein, as a non-invasive marker for gut injury and prognosis in AD cirrhosis.
METHODS: Serum VIL1 was measured in 338 cirrhosis patients (discovery n = 130, validation n = 208, including acute-on-chronic liver failure [ACLF]) from MICROB-PREDICT cohorts and 50 healthy controls (HC). Duodenal biopsies (n = 49 patients, n = 11 HC) were assessed for tissue VIL1 via immunohistochemistry. Serum cytokine profiling linked serum VIL1 levels to systemic inflammation.
RESULTS: Compared to HC, both serum and tissue VIL1 levels were lower in stable AD patients. However, serum VIL1 progressively increased with AD severity, peaking in ACLF. Serum VIL1 was associated with 90-day mortality (AUROC: 0.721, p < 0.001; similar to MELD: 0.722, p < 0.001). A cut-off > 12.79 ng/mL enhanced the prognostic accuracy provided by severe disease stage, defined as CLIF-C AD score ≥ 50 or ACLF (low VIL1: 17.5% vs. high VIL1: 53.6% mortality). This threshold was associated with increased systemic inflammation, suggesting enhanced bacterial translocation. VIL1 was an independent predictor of 90-day mortality (HR: 2.52, CI: 1.648-3.848, p < 0.001) in Cox regression. All findings were confirmed in the validation cohort.
CONCLUSION: Serum VIL1 is a non-invasive indicator of gut barrier damage and short-term mortality in AD cirrhosis. Incorporating VIL1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
AIM: We investigated serum villin-1 (VIL1), an epithelial brush-border associated actin-binding protein, as a non-invasive marker for gut injury and prognosis in AD cirrhosis.
METHODS: Serum VIL1 was measured in 338 cirrhosis patients (discovery n = 130, validation n = 208, including acute-on-chronic liver failure [ACLF]) from MICROB-PREDICT cohorts and 50 healthy controls (HC). Duodenal biopsies (n = 49 patients, n = 11 HC) were assessed for tissue VIL1 via immunohistochemistry. Serum cytokine profiling linked serum VIL1 levels to systemic inflammation.
RESULTS: Compared to HC, both serum and tissue VIL1 levels were lower in stable AD patients. However, serum VIL1 progressively increased with AD severity, peaking in ACLF. Serum VIL1 was associated with 90-day mortality (AUROC: 0.721, p < 0.001; similar to MELD: 0.722, p < 0.001). A cut-off > 12.79 ng/mL enhanced the prognostic accuracy provided by severe disease stage, defined as CLIF-C AD score ≥ 50 or ACLF (low VIL1: 17.5% vs. high VIL1: 53.6% mortality). This threshold was associated with increased systemic inflammation, suggesting enhanced bacterial translocation. VIL1 was an independent predictor of 90-day mortality (HR: 2.52, CI: 1.648-3.848, p < 0.001) in Cox regression. All findings were confirmed in the validation cohort.
CONCLUSION: Serum VIL1 is a non-invasive indicator of gut barrier damage and short-term mortality in AD cirrhosis. Incorporating VIL1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.